Cargando…

Hepatocellular carcinoma after direct-acting antivirals: an unresolved problem. Review of five cases

AIM OF THE STUDY: To present the problem of hepatocellular carcinoma (HCC) occurring in patients treated with direct-acting antiviral (DAA) agents and to draw attention to the fact that HCC may develop even after successful therapy and in patients who were not previously diagnosed with it. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartosiewicz, Agnieszka Joanna, Mikuła, Tomasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431094/ https://www.ncbi.nlm.nih.gov/pubmed/30915412 http://dx.doi.org/10.5114/ceh.2019.83162

Ejemplares similares

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Unresolved theoretical problems
por: Vogt, E W
Publicado: (1983)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Unresolved problems with distress screening
por: Fielding, R, et al.
Publicado: (2013)

The Unresolved Problem of DNA Bridging
por: Fernández-Casañas, María, et al.
Publicado: (2018)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals
por: Cabral, Loraine Kay D., et al.
Publicado: (2022)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis
por: Váncsa, Szilárd, et al.
Publicado: (2021)

Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
por: Dias, Cátia, et al.
Publicado: (2018)

Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment – preliminary report
por: Warzyszyńska, Karola, et al.
Publicado: (2017)

No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis
por: Rutledge, Stephanie M., et al.
Publicado: (2019)

Resolved and unresolved bioethical authenticity problems
por: Ahlin Marceta, Jesper
Publicado: (2020)

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients
por: Fouad, Magdy, et al.
Publicado: (2021)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues
por: Tampaki, Maria, et al.
Publicado: (2018)

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
por: Kamp, William M., et al.
Publicado: (2019)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
por: Frazzoni, Leonardo, et al.
Publicado: (2021)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
por: Rinaldi, Luca, et al.
Publicado: (2020)

Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals
por: Pascut, Devis, et al.
Publicado: (2019)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2021)

Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria
por: Ochi, Hironori, et al.
Publicado: (2020)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
por: Imamura, Taisuke, et al.
Publicado: (2022)

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus
por: Mawatari, Seiichi, et al.
Publicado: (2022)

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
por: Vernuccio, Federica, et al.
Publicado: (2022)

Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
por: Watanabe, Takao, et al.
Publicado: (2023)

Opisthorchiasis and cholangiocarcinoma in Southeast Asia: an unresolved problem
por: Hughes, Thomas, et al.
Publicado: (2017)

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals
por: Tachi, Yoshihiko, et al.
Publicado: (2017)

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
por: Syed, Taseen, et al.
Publicado: (2018)

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
por: Dash, Srikanta, et al.
Publicado: (2020)

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
por: Teng, Wei, et al.
Publicado: (2019)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Spontaneous Rupture of Hepatocellular Carcinoma With Fatal Outcome in a Patient Taking Direct-Acting Antivirals
por: Dendane, Youness, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qlccs9n8ao7irdv86cstuc19ne